Inflammatory mediators of hepatic steatosis

Mediators Inflamm. 2010:2010:837419. doi: 10.1155/2010/837419. Epub 2010 Mar 16.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a world-wide public health problem. NAFLD represents a spectrum of disease ranging from "simple steatosis", which is considered relatively benign, to nonalcoholic steatohepatitis and to NAFLD-associated cirrhosis and end-stage liver disease. The etiology of NAFLD and its progression is complex and remains incompletely understood. The progression of the disease involves many factors. Apart from the two hits, the accumulation of TG and the development of fibrosis and necroinflammatory processes, exit numerous molecules associated with these two hits. Among them we can highlight the pro-inflammatory molecules and adiponectins. This review focuses on the growing evidence from both experimental and human studies suggesting a central role of cytokines in the pathogenesis of NAFLD. We review the role of cytokines as key regulators of insulin sensitivity and hepatic lipid overloading, liver injury and inflammation, and fibrosis with an emphasis on potential therapeutic implications.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Fatty Liver / immunology*
  • Fatty Liver / pathology
  • Fatty Liver / physiopathology
  • Fatty Liver / therapy
  • Humans
  • Inflammation / immunology*
  • Inflammation / pathology
  • Inflammation / physiopathology
  • Inflammation Mediators / immunology*
  • Obesity / physiopathology
  • Oxidative Stress
  • Risk Factors

Substances

  • Inflammation Mediators